Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
858 TILKine-2: a novel best-in-class tumor infiltrating lymphocyte (TIL) targeting engineered IL-2 with superior pre-clinical efficacy and safety for immunotherapy of cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.